Lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
== Society and culture == PRP has received attention in media as a result of its use by athletes. In the 2010s, cosmetic procedures marketed under the name of "vampire facials" grew in popularity, fueled by celebrity endorsement. These facials generally center on PRP treatment, and usually involve microneedling. In April 2024, the CDC announced that three women who had been patients at the Albuquerque, New Mexico, VIP Spa had been diagnosed with HIV after getting such facials; another almost 200 former clients and their sexual partners tested negative. Investigations by New Mexico and federal health officials revealed that the woman performing the procedures was operating out of an unlicensed medical spa, practicing without a medical license, and reusing blood-contaminated equipment intended for single-patient use without sterilization between patients. PRP has been injected into the vagina, in a procedure called "O-shot" or "orgasm shot", with claims to improve orgasms. No evidence supports such claims.
== MTRR gene == The Methionine Synthase Reductase (MTRR) gene primarily acts in the reductive regeneration of cob(I)alamin (vitamin B12). Cob(I)alamin is a cofactor that maintains activation of the methionine synthase enzyme (MTR) methionine synthase, linking folate and methionine metabolism. Donation of methyl groups from folate are utilized for cellular and DNA methylation, influencing epigenetic inheritance.
==== Elimination ==== With a single oral dose of radiolabeled gepirone, 81% is recovered in urine and 13% is recovered in feces as metabolites. About 60% of the gepirone is eliminated in urine within 24 hours. The terminal half-life of gepirone as the extended-release form is approximately 5 hours.
==== Australia ==== The Australia New Zealand Food Standards Code defines cider as "fruit wine prepared from the juice or must of apples and no more than 25% of the juice or must of pears". Cider has been made in Australia since its early settlement. Primarily this production has been for limited local usage, with national commercial distribution and sales dominated by brewery owned brands such as: Mercury Cider, Strongbow and imported ciders such as Somersby and Rekordelig With the growth in interest in cider, the number of local producers has increased. Some cider producers are attempting to use more traditional methods and traditional cider apple varieties such as Henry of Harcourt and Crucible in S.W. Victoria. In Western Australia, the number of cider producers has also grown in the southwest region, particularly in areas where wine is also produced.
It works through crystal lattice beads, which are coated with ligand coupling molecules and filled with cerium ions. These give off bursts of light when stimulated by an isotope, which can easily be measured. Ligands are radiolabeled using either 3H or 125I, and released into the assay. Since only the radioligands that directly bind to the beads initiate a signal, free-ligands do not interfere during the screening process. Conformational structure and vibrational motions can change between a protein's ligand-free and its ligand-bound state. The Structural Dynamics Response Assay (SDR) detects ligand-mediated changes to the natural motion of a target protein. These changes can be coupled to the light output intensity of a luciferase sensor protein fused to the target protein to provide a highly sensitive measure of ligand binding. Further, the SDR assay does not require labeled ligands, separation steps, or thermal gradients, and has been shown to work in assay volumes as low as 6 uL.
Sources: en.wikipedia.org
==== Initial vice presidential conflict ==== In conflict with Vice President Verónica Abad Rojas from the very first days of his mandate, he distanced her by appointing her "peace collaborator" between Israel and the Palestinians, a mission she was to carry out from the Ecuadorian embassy in Tel Aviv. At the same time, he announced the reorganisation of the vice presidency in order to reduce its powers. Abad Rojas accused him of sending her "to die in the war". Indeed, Noboa sent Abad Rojas to Israel just weeks after diplomats were being evacuated from Israel due to the October 7 attacks, and with decreased security while she remained outside of Ecuador.
== History == Founded as the "Association of Clinical Biochemists", the association has evolved as biochemistry has changed with advances in laboratory medicine. Recognizing an increasing number of medical members, the name was changed in 2005 to "Association for Clinical Biochemistry". In 2007 the "Association of Clinical Scientists in Immunology" merged with the ACB. The membership expanded in 2010 with the merger with the "Association of Clinical Microbiologists". The broader nature of the membership contributed to its renaming as ACB in 2013. The name was abbreviated to the Association for Laboratory Medicine in 2024.
Dimethoxytrityl, [bis-(4-methoxyphenyl)phenylmethyl] (DMT) — Removed by weak acid. DMT group is widely used for protection of 5'-hydroxy group in nucleosides, particularly in oligonucleotide synthesis. Methoxytrityl [(4-methoxyphenyl)diphenylmethyl] (MMT) – Removed by acid and hydrogenolysis. Benzyloxymethyl — Comparable stability to MOM, MEM und SEM, but also admits reductive removal: sodium in liquid ammonia, catalytic hydrogenation (palladium hydroxide on activated carbon), or Raney nickel in ethanol Ethoxyethyl ethers (EE) – Cleavage more trivial than simple ethers e.g. 1N hydrochloric acid Methoxyethoxymethyl ether (MEM) — Removed by hydrobromic acid in tetrahydrofuran or zinc bromide in dichloromethane Methoxymethyl ether (MOM) — Removed by 6 M hydrochloric acid in tetrahydrofuran/water Tetrahydropyranyl (THP) — Removed by acetic acid in tetrahydrofuran/water, p‑toluenesulfonic acid in methanol Methylthiomethyl ether — Removed by acid or soft metal oxidants: base-buffered mercuric chloride in wet acetonitrile or silver nitrate in wet tetrahydrofuran Tris(isopropyl)silyloxymethyl (TOM) — Commonly protects 2'-hydroxy function in oligonucleotide synthesis. β‑(Trimethylsilyl)ethoxymethyl — More labile than MEM and MOM to acid hydrolysis: 0.1 M hydrochloric acid in methanol, concentrated hydrofluoric acid in acetonitrile, boron trifluoride etherate in dichloromethane, or tetrabutylammonium fluoride in HMPT (Hexamethyl phosphoric acid triamide) or in tetrahydrofuran Other ethers:
== Uses == In the US, glycine is typically sold in two grades: United States Pharmacopeia ("USP"), and technical grade. USP grade sales account for approximately 80 to 85 percent of the U.S. market for glycine. If purity greater than the USP standard is needed, for example for intravenous injections, a more expensive pharmaceutical grade glycine can be used. Technical grade glycine, which may or may not meet USP grade standards, is sold at a lower price for use in industrial applications, e.g., as an agent in metal complexing and finishing.
Ethanol is classified as a teratogen—a substance known to cause birth defects; according to the U.S. Centers for Disease Control and Prevention (CDC), alcohol consumption by women who are not using birth control increases the risk of fetal alcohol spectrum disorders (FASDs). This group of conditions encompasses fetal alcohol syndrome, partial fetal alcohol syndrome, alcohol-related neurodevelopmental disorder, static encephalopathy, and alcohol-related birth defects. The CDC currently recommends complete abstinence from alcoholic beverages for women of child-bearing age who are pregnant or trying to become pregnant.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.